Clinical outcomes of interactive, intensive and individual (3i) play therapy for children with ASD: a two-year follow-up study.

Autor: Tilmont Pittala, Elodie, Saint-Georges-Chaumet, Yann, Favrot, Claire, Tanet, Antoine, Cohen, David, Saint-Georges, Catherine
Předmět:
Zdroj: BMC Pediatrics; 5/12/2018, Vol. 18 Issue 1, pN.PAG-N.PAG, 1p, 4 Charts, 3 Graphs
Abstrakt: Background: The outcomes of psycho-educational interventions for Autism Spectrum Disorders (ASDs) comorbid with severe to moderate intellectual disability (ID) are insufficiently documented. In this prospective study, we examined a developmental individual, interactive and intensive approach, called the '3i method', which is based on play therapy.Methods: Twenty DSM-IV-TR ASD subjects (mean chronological age 63.8 ± 37.8 months; mean developmental age 19.5 ± 6.6 months) were included and followed the 3i method for 24 months. Developmental and behavioural skills were assessed at baseline and after 24 months using the VABS, PEP-R and Nadel Imitation scale. Autism severity was evaluated using the Child Autism Rating Scale (CARS) and the Autism Diagnostic Interview (ADI-R).Results: After 2 years of the 3i method, our 3 primary outcome variables significantly increased (VABS developmental age of socialization increased by 83%, age of communication by 34%, and Nadel Imitation score by 53%). Almost all VABS and PEP-R domains significantly improved. Additionally, increases in the VABS socialization score were positively correlated with the total number of treatment hours and CARS score; all ADI-R areas significantly decreased; and diagnoses had changed in 47.5% of the subjects (37% for PDD-NOS and even 10.5% for ID without PDD).Conclusion: Children who followed the 3i method for 2 years had significantly improved behavioural and developmental skills and showed a clear decrease in autism severity. These results suggest that the 3i method may be useful for autistic children by improving their daily interactions with their social environment.Trial Registration: was retrospectively registered on May 20th, 2014 by the French Agency for drug and health (ANSM) under number ID-RCB 2014-A00542-45, reference: B148558-31. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: